Evicenter
MarkdownMedical informationP&T meetings
Ifezuntirgene inilparvovec (AMT-130)

Huntington's disease

Manufacturer
uniQure
Launch
Not announced
Last updated
291 sources

Section 4 of 6

Clinical evidence

192 evidence topics · 48 sources

Study summaries

Pooled phase I/II analysis versus external control

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using cUHDRS change at 36 months as the primary endpoint
Components of the cUHDRS as described by the sponsor
Statistical analysis description
Number of participants (Planned and analyzed)
Participants with data at each visit in the three-year analysis, high dose
Group and endpointBaseline12 months24 months36 months
AMT-130 high dose (cUHDRS and TFC)“17”“17”“15”“12”
PSM external control, cUHDRS“940”“715”“586”“568”
PSM external control, TFC“940”“725”“597”“583”
Participants with data at each visit in the four-year analysis, high dose
Group and endpointBaseline12 months24 months36 months48 months
AMT-130 high dose (cUHDRS and TFC)“17”“17”“15”“15”“12”
Enroll-HD B, cUHDRS“1337”“953”“760”“690”“625”
Enroll-HD B, TFC“1337”“967”“772”“704”“641”
Enroll-HD A, cUHDRS (post hoc)“619”“484”“398”“355”“349”
Enroll-HD A, TFC (post hoc)“619”“492”“401”“360”“364”
Participants with cerebrospinal fluid neurofilament light chain samples, through 48 months
Description of analysis sets
Derivation of the Enroll-HD external control arm analysis set
StepParticipants
Diagnosis of HD in ENROLL-HD“N = 19,542”
Met AMT-130 eligibility criteria“N = 6,596 (33.8%)”
Did not meet AMT-130 eligibility criteria“N = 12,946”
Excluded from the analysis set“N = 3,326”
External control arm analysis set“N = 3,270 (49.6%)”
Propensity-score matched to High-Dose cohort“N = 940”
Results
Participant disposition
Baseline characteristics
Demographic and baseline characteristics of the high-dose cohort and the propensity score-matched external control
Characteristic, mean (SD)AMT-130 high dose (N=17)PSM external control, Enroll-HD (N=940)
Sex, males (%)“47.1”“55.6”
Age“45.8”“45.2”
CAG repeats“42.4”“42.8”
CAP100 score“86.2”“86.8”
DCL = 3, 4 (%)“35.3, 64.7”“30.5, 69.5”
PIN score“0.77”“0.81”
cUHDRS“14.9”“14.7”
TFC“12.2”“12.1”
SDMT“46.1”“45.3”
SWRT“89.9”“87.6”
TMS“12.1”“11.6”
HD-ISS Stage 2, 3 (%)“47.1, 52.9”“51.6, 48.4”
Region; No. America, Other (%)“58.8, 41.2”“28.9, 71.1”
Efficacy results
Cerebrospinal fluid neurofilament light chain at 2 and 3 years, high dose
TimepointParticipantsCSF NfL mean change from baseline
Year 2“N = 15”“-9.7%”
Year 3“N = 11”“-8.2%”
Primary analysis at 48 months: other secondary endpoints, high dose
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Adverse events in Cohorts 1 to 3, June 2025 data cutoff
Adverse event, N (%)Sham surgery (n=10)Low-dose AMT-130, Cohort 1 (n=13)High-dose AMT-130, Cohort 2 (n=20)Dose-blinded, Cohort 3 (n=12)All AMT-130, Cohorts 1, 2 and 3 (n=45)
Any TEAEs“10”( “100.0”)“12”( “92.3”)“20”( “100.0”)“12”( “100”)“44”( “97.8”)
Any SAEs“1”( “10.0”)“3”( “23.1”)“9”( “45.0”)“3”( “25”)“15”( “33.3”)
Any SAEs (peri-operative)“1”( “10.0”)“2”( “15.4”)“6”( “30.0”)“0”( “0.0”)“8”( “17.8”)
Any drug-related TEAE“0”( “0.0”)“0”( “0.0”)“6”( “30.0”)“3”( “25.0”)“9”( “20.0”)
Any drug-related SAE“0”( “0.0”)“0”( “0.0”)“4”( “20.0”)“0”( “0.0”)“4”( “8.8”)
Headache“3”( “30.0”)“3”( “23.1”)“9”( “45.0”)“6”( “50.0”)“18”( “40.0”)
Procedural headache“5”( “50.0”)“4”( “30.8”)“10”( “50.0”)“2”( “16.7”)“16”( “35.6”)
Procedural pain“6”( “60.0”)“2”( “15.4”)“7”( “35.0”)“2”( “16.7”)“11”( “24.4”)
Post lumbar puncture syndrome“6”( “60.0”)“2”( “15.4”)“5”( “25.0”)“2”( “16.7”)“10”( “22.2”)
Procedural complication“4”( “40.0”)“4”( “30.8”)“5”( “25.0”)“0”( “0.0”)“9”( “20.0”)
Anxiety“0”( “0.0”)“0”( “0.0”)“4”( “20.0”)“4”( “33.3”)“8”( “17.8”)
Constipation“0”( “0.0”)“0”( “0.0”)“2”( “10.0”)“6”( “50.0”)“8”( “17.8”)
Insomnia“0”( “0.0”)“1”( “7.7”)“1”( “5.0”)“6”( “50.0”)“8”( “17.8”)
Back pain“1”( “10.0”)“0”( “0.0”)“0”( “0.0”)“5”( “41.7”)“5”( “11.1”)
Adverse events in all 51 treated participants, June 2026 data cutoff
Adverse event, N (%)Sham surgery (n=10)Low-dose AMT-130, Cohort 1 (n=13)High-dose AMT-130, Cohort 2 (n=20)Dose-blinded AMT-130, Cohort 3 (n=12)High-dose AMT-130, Cohort 4 (n=6)All AMT-130, Cohorts 1, 2, 3 and 4 (n=51)
Any TEAEs“10”( “100.0”)“12”( “92.3”)“20”( “100.0”)“12”( “100”)“6”( “100”)“50”( “98”)
Any SAEs“1”( “10.0”)“4”( “30.8”)“10”( “50.0”)“4”( “33.3”)“2”( “33”)“20”( “39.2”)
Any SAEs (peri-operative)“1”( “10.0”)“2”( “15.4”)“6”( “30.0”)“0”( “0.0”)“1”( “16.7”)“9”( “17.6”)
Any drug-related TEAE“0”( “0.0”)“0”( “0.0”)“6”( “30.0”)“3”( “25.0”)“2”( “33.3”)“11”( “21.5”)
Any drug-related SAE“0”( “0.0”)“0”( “0.0”)“4”( “20.0”)“0”( “0.0”)“1”( “16.7”)“5”( “9.80”)
Headache“3”( “30.0”)“2”( “15.4”)“9”( “45.0”)“6”( “50.0”)“4”( “66.7”)“21”( “41.2”)
Procedural headache“5”( “50.0”)“4”( “30.8”)“10”( “50.0”)“2”( “16.7”)“0”( “0.0”)“16”( “31.4”)
Procedural pain“6”( “60.0”)“2”( “15.4”)“7”( “35.0”)“3”( “25.0”)“1”( “16.7”)“13”( “25.5”)
Post lumbar puncture syndrome“6”( “60.0”)“2”( “15.4”)“6”( “30.0”)“2”( “16.7”)“0”( “0.0”)“10”( “19.6”)
Procedural complication“4”( “40.0”)“3”( “23.1”)“4”( “20.0”)“0”( “0.0”)“0”( “0.0”)“7”( “13.7”)
Anxiety“0”( “0.0”)“0”( “0.0”)“4”( “20.0”)“4”( “33.3”)“3”( “50.0”)“11”( “21.6”)
Constipation“0”( “0.0”)“0”( “0.0”)“2”( “10.0”)“6”( “50.0”)“1”( “16.7”)“9”( “17.6”)
Insomnia“0”( “0.0”)“1”( “7.7”)“1”( “5.0”)“6”( “50.0”)“2”( “33.3”)“10”( “19.6”)
Back pain“1”( “10.0”)“0”( “0.0”)“0”( “0.0”)“5”( “41.7”)“0”( “0.0”)“5”( “9.8”)
Procedural nausea“0”( “0.0”)“3”( “23.1”)“3”( “15.0”)“1”( “8.3”)“2”( “33.3”)“9”( “17.6”)
Paraesthesia“1”( “10.0”)“0”( “0.0”)“1”( “5.0”)“1”( “8.3”)“2”( “33.3”)“4”( “7.8”)
Sleep disorder“0”( “0.0”)“0”( “0.0”)“0”( “0.0”)“4”( “33.3”)“0”( “0.0”)“4”( “7.8”)
Sensory loss“0”( “0.0”)“0”( “0.0”)“0”( “0.0”)“1”( “8.3”)“2”( “33.3”)“3”( “5.9”)
Study limitations
Summary
  • External comparison: efficacy is assessed against a propensity score-matched external control from the Enroll-HD natural history data set. The Form 10-K states that the analyses rely on external historical controls and that these may not be accepted as a basis for regulatory approval. After a Type A meeting in January 2026, the FDA stated that it cannot agree that these data are sufficient as primary evidence of effectiveness. One commentary noted that the evidence of efficacy “depends entirely on the ENROLL-HD controls being well-matched”.
  • Open-label treatment: the same commentary noted that most participants were in open-label arms, so a placebo effect is possible. An analysis of the GENERATION HD1 placebo arm found a placebo response on the cognitive scores (SDMT and SWR), which also influences the cUHDRS.
  • Matching covariates: MRI data were not collected in Enroll-HD, so striatal volume, a predictor of decline and an eligibility criterion of the phase I/II studies, could not be matched. The sponsor analysis used baseline age, sex, CAP100, DCL, TFC, TMS, SDMT, and SWR and reports that other covariates can substitute for striatal volume. A comment submitted to ICER listed limits of the natural history comparison, including bias from selection into a surgical trial versus a registry, different visit schedules, and very small numbers of treated patients at longer follow-up.
  • Small numbers: 12 high-dose participants contributed 36-month data to the three-year analysis, 15 to the updated 36-month analysis, and 12 to the 48-month analysis; CSF NfL was available for 11 high-dose participants at 36 months in the three-year analysis.
  • Missing data and changes in the control: missingness in the updated Enroll-HD matched controls reached 53% at 48 months, controls with longer follow-up declined more slowly, and decline in Enroll-HD B was 20% slower than in Enroll-HD A at 48 months. Against Enroll-HD B the 48-month cUHDRS result did not reach statistical significance (p=0.144); the result against Enroll-HD A comes from a post-hoc sensitivity analysis. A news report on the four-year analysis noted that the natural history database is updated, which “can alter results”.
  • Analysis choices and nominal p-values: the June 2025 release described a propensity score-weighted primary analysis, while the September 2025 release reports the propensity score-matched comparison as the prespecified primary analysis. The 24-month comparison with a propensity-weighted external control of 154 participants was a post-hoc analysis. Several p-values are nominal, which the Form 10-K states regulators may weigh less than standard p-values.
  • Reporting: the results are reported in company press releases, presentations, and SEC filings. One commentary noted that individual data points are not shown, error bars are not defined, data from imitation (sham) procedure participants are not shown, and there are no data on mutant HTT lowering.
Missing data and survivor bias in the updated Enroll-HD external control
Enroll-HD B participants, by last available dataAnnualized cUHDRS change from baseline
Participants with last data at Y1“-0.91”
Participants with last data at Y2“-0.82”
Participants with last data at Y3“-0.73”
Participants with last data at Y4 or more“-0.41”
Effect of volumetric criteria on 3-year decline in TRACK-HD, TRACK-ON, and PREDICT-HD
AnalysisVolumetric criteria applied (N = 232)Volumetric criteria not applied (N = 442)
cUHDRS mean change from baseline to 3 years, unweighted“-1.4”“-1.7”
cUHDRS mean change from baseline to 3 years, PS weighted“-1.4”“-1.4”
TFC mean change from baseline to 3 years, unweighted“-1.0”“-1.2”
TFC mean change from baseline to 3 years, PS weighted“-0.9”“-0.9”

CT-AMT-130-01

Objective
Location and study date
United States study sites in the registry record
SiteCity
University of Alabama at Birmingham“Birmingham”
University of Arizona (Surgical Site Only)“Tucson”
University of California, San Francisco“San Francisco”
CenExel Rocky Mountain Clinical Research“Englewood”
Rush University Medical Center“Chicago”
Johns Hopkins University“Baltimore”
University of Michigan Department of Neurology“Ann Arbor”
Ohio State University“Columbus”
Vanderbilt University Medical Center“Nashville”
The University of Texas“Houston”
Virginia Commonwealth University VCU School of Medicine, Department of Neurology“Richmond”
University of Washington Medical Center“Seattle”
Study dates in the registry record
DateRegistry value
Study start (actual)“2019-09-06”
Primary completion (estimated)“2029-06”
Study completion (estimated)“2029-12”
Last update posted“2025-10-21”
Study dates in the original registry record, October 2019, superseded
Study design
Design fields in the current registry record
Randomized, triple-masked sequential design with crossover: registry version 33, October 2024, superseded
Eligibility criteria
Treatment
Study outcomes
Rationale for using adverse events as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Estimated total enrollment in the current registry record
FieldRegistry value
Enrollment (estimated)“43”
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Cohort 4 baseline characteristics
Characteristic (mean or %)AMT-130 high-dose Cohort 4 (n=6)
Sex, males (%)“16.7”
Age“43.7”
CAG repeats“44.5”
DCL = 3, 4 (%)“16.7, 83.3”
TFC“12.0”
Efficacy results
U.S. interim analysis: clinical measures against baseline, controls, and a TRACK-HD natural history cohort, June 2023
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Study limitations
Summary
  • Changed blinding and registry inconsistencies: the current ClinicalTrials.gov record lists allocation as non-randomized and masking as none (open label), while its official title describes a randomized, double-blind, sham control and open-label study. Version 1 (2019) listed a randomized, quadruple-masked design with an estimated enrollment of 26 and a blinded 18-month core period; version 33 (2024) listed a randomized, triple-masked design with an estimated enrollment of 37 and a blinded 12-month core period; the current record lists an estimated enrollment of 43. Cohort 4 is open-label.
  • Short randomized comparison: the sham comparison in Cohorts 1 and 2 covered the blinded 12-month period, after which sham participants could cross over. Four of the six control participants in the high-dose cohort crossed over and the other two did not meet the inclusion criteria, and interim analyses compared treated participants with control participants only up to 12 months and excluded efficacy data from crossover participants.
  • Small numbers: Cohorts 1 and 2 randomized 26 participants (six low dose, 10 high dose, 10 sham); Cohort 3 enrolled 12 and Cohort 4 six.
  • Safety as the primary outcome: the study is designed to establish safety and proof-of-concept, and the registered primary outcome is adverse events at 12 months.
  • Target engagement: the company states that CSF mutant huntingtin is not believed to be materially representative of mutant huntingtin in the targeted brain regions, and one commentary noted that there are no data on mutant HTT lowering.
  • Protocol changes: version 1 required ≥44 CAG repeats and an imitation surgery with bilateral partial thickness burr holes; the current record requires ≥40 CAG repeats and a simulated procedure with skin incisions only and no burr holes. Cohort 3 was first planned to study alternative stereotactic navigation systems and was redesigned to study perioperative immunosuppression.

CT-AMT-130-02

Objective
Location and study date
Study sites and dates in the ClinicalTrials.gov record
FieldRegistry value
Site, Warsaw, Poland“Instytut Psychiatrii i Neurologii”
Site, Warsaw, Poland“Interventional Neuro Center”
Site, Cardiff, United Kingdom“Cardiff University”
Site, London, United Kingdom“National Hospital for Neurology & Neurosurgery”
Study start (actual)“2021-10-07”
Primary completion (estimated)“2029-03”
Study completion (estimated)“2029-10-07”
EU trial record after transition to the Clinical Trials Regulation
FieldRecord value
Protocol code“CT-AMT-130-02”
Transition trial“Yes”
Locations“Poland”
Start of trial“Start of trial 07/10/2021”
Current status in Poland“Ongoing, recruitment ended”
Recruitment end in Poland“15/10/2024”
Estimated global end date“31/12/2029”
Study design
Trial design fields in the EU Clinical Trials Register
FieldRegister value
Controlled“No”
Randomised“No”
Open“Yes”
Double blind“No”
Eligibility criteria
Treatment
Investigational product concentration in the EU Clinical Trials Register
Study outcomes
Rationale for using safety measures as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment in the ClinicalTrials.gov record
FieldRegistry value
Enrollment (actual)“14”
Description of analysis sets

No evidence found.

Results
Participant disposition
Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Safety notifications in the EU trial record
NotificationRecord value
Serious breach“Serious Breach (0)”
Unexpected event“Unexpected Event (0)”
Urgent safety measure“Urgent Safety Measure (0)”
Temporary halt“Temporary Halt (0)”
Study limitations
Summary
  • Open-label, uncontrolled design with inconsistent records: the EU Clinical Trials Register lists the trial as not controlled, not randomised, open, and not double blind. The ClinicalTrials.gov record describes open-label Cohorts 1 and 2 and randomization in Cohort 3 only, lists allocation as randomized and masking as none (open label), and gives an official title describing a randomized, double-blind study; version 1 (2022) listed a non-randomized, open-label design with an estimated enrollment of 15.
  • Enrollment: 15 participants were planned (six low dose, nine high dose). The Form 10-K reports 13 participants enrolled and treated (six low dose, seven high dose), while the ClinicalTrials.gov record lists an actual enrollment of 14.
  • Sites: the February 2022 release named sites in Poland, the United Kingdom, and Germany; the ClinicalTrials.gov record lists sites in Poland and the United Kingdom, and the CTIS record lists Poland.
  • Results reporting: the pooled-analysis protocols pool data across the U.S. and EU studies, and the registered primary outcomes are safety and tolerability measures, including adverse events.
  • Safety: suspected unexpected severe adverse reactions occurred in two high-dose participants treated at a single clinical site.

Planned confirmatory trial

Objective

No evidence found.

Location and study date
Study design
Eligibility criteria

No evidence found.

Treatment
Study outcomes
Rationale for using total functional capacity as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary
  • Planned design only: the trial is described in company releases and the Form 10-Q as a randomized, standard-of-care-controlled trial of approximately 200 participants randomized 2:1, with TFC at 36 months as the primary endpoint, and screening is planned to begin in the United States by the end of 2026.
  • Control without a sham procedure: after a Type A meeting in January 2026 the FDA strongly recommended a prospective, randomized, double-blind, sham surgery-controlled study; in 2026 it later sought alignment on a confirmatory design that included consideration of a randomized standard-of-care control instead of a sham procedure.
  • Primary endpoint: the UHDRS TFC appears to have a ceiling effect in early stage Huntington's disease, and it lacks core clinimetric data on test-retest reliability and internal consistency.
  • Timing: the FDA stated that the confirmatory study should be well underway, and potentially fully enrolled, at the time of accelerated approval; the company expects the study to be well underway by the time of potential approval.